Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
85.93(c) 85.72(c) 86.16(c) 85.79(c) 84.95(c) Last
7 018 372 14 077 671 3 545 905 3 129 810 3 694 713 Volume
+0.88% -0.24% +0.51% -0.43% -0.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,6x
Yield 2021 3,54%
Sales 2022 53 872 M - -
Net income 2022 10 930 M - -
Net Debt 2022 17 542 M - -
P/E ratio 2022 18,7x
Yield 2022 3,65%
Capitalization 208 B 208 B -
EV / Sales 2021 4,46x
EV / Sales 2022 4,18x
Nbr of Employees 110 000
Free-Float 87,4%
More Financials
Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and... 
Sector
Pharmaceuticals
Calendar
06/23Presentation
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVARTIS AG
05:23pNOVARTISá : Positive survival data for Novartis investigational radioligand ther..
PU
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
10:16aNOVARTISá : Kesimpta data show long-term preservation of IgG/IgM levels and no i..
AQ
06:45aNOVARTISá : Joins Hewlett Packard Enterprise to Expand Healthcare Access
MT
01:39aNOVARTISá : and Hewlett Packard Enterprise join forces to advance Novartis globa..
PU
06/22NOVARTISá : Therapy Kesimpta Preserves Immunoglobulin Levels in Relapsing Multip..
MT
06/22Novartis to Produce Over 50 Million BioNTech-Pfizer COVID-19 Vaccine Doses in..
MT
06/22European Medicines Agency OKs Two New Manufacturing Sites for Pfizer-BioNTech..
MT
06/22NOVARTISá : aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine i..
RE
06/22EU Approves Two More Manufacturing Sites for Pfizer-BioNTech Covid Vaccine
DJ
06/22NOVARTISá : Kesimpta« (ofatumumab) data show long-term preservation of IgG/IgM l..
PU
06/20NOVARTISá : Gene Therapy Zolgensma Shows Efficacy in Children With Spinal Muscul..
MT
06/18NOVARTISá : Study Shows Improved Motor Function in Children with Spinal Muscular..
MT
06/18PRESS RELEASEá : Novartis: New Zolgensma data -3-
DJ
06/18PRESS RELEASEá : Novartis: New Zolgensma data -2-
DJ
More news
News in other languages on NOVARTIS AG
12:16pBourse Zurich: la séance se termine sur une note nettement négative
12:15pAktien Schweiz Schluss: Pharmaschwergewichte setzen SMI unter Druck
11:46aAktien Schweiz bauen Vortagesverluste deutlich aus
09:22aDPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 23.06.2021 - 15.15 Uhr
05:40aAktien Schweiz: Konsolidierungskurs setzt sich fort
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 92,50 $
Average target price 106,66 $
Spread / Average Target 15,3%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.56%209 282
JOHNSON & JOHNSON3.34%430 876
ROCHE HOLDING AG11.75%324 905
PFIZER, INC.6.09%221 725
ABBVIE INC.6.39%202 586
ELI LILLY AND COMPANY28.58%201 295